Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies ...

Thyroid cancer-associated syndromes, including multiple endocrine neoplasia type 2, were significantly more prevalent than current estimates.

It is the second phase 3 trial flop for highly touted Truqap, which was approved in November of 2023 in a narrow group of HR-positive, HER2-negative breast cancers with certain genetic alterations.

They also highlighted the value of having a well-tolerated treatment that delays their cancer getting worse and targets AKT1 or PTEN gene alterations, noting that there are currently none available." ...

The phase II ROME trial demonstrated that personalized therapy guided by combined tissue and liquid biopsies significantly ...

PINK1 (PTEN induced kinase 1) is a novel gene recently identified as causative in autosomal recessive early onset parkinsonism (PARK6). In the present study, we examined the localisation of PINK1 in ...

In this article, we are going to take a look at where Patterson-UTI Energy, Inc. (NASDAQ:PTEN) stands against the other growth stocks under $10. Growth stocks refer to companies that grow their ...

PATTERSON-UTI ENERGY insiders have traded $PTEN stock on the open market 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales ...

Patterson-UTI Energy, Inc. (NASDAQ:PTEN) will pay a dividend of $0.08 on the 16th of June. This makes the dividend yield 5.3%, which will augment investor returns quite nicely. We've discovered 3 ...

A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him. Researchers described the case in a new study ...